Schmitz Klaus Jürgen, Grabellus Florian, Callies Rainer, Otterbach Friedrich, Wohlschlaeger Jeremias, Levkau Bodo, Kimmig Rainer, Schmid Kurt Werner, Baba Hideo Andreas
Institute of Pathology, University Hospital of Essen-Duisburg, Essen, Germany.
Breast Cancer Res. 2005;7(2):R194-203. doi: 10.1186/bcr977. Epub 2005 Jan 7.
Focal adhesion kinase (FAK) regulates multiple cellular processes including growth, differentiation, adhesion, motility and apoptosis. In breast carcinoma, FAK overexpression has been linked to cancer progression but the prognostic relevance remains unknown. In particular, with regard to lymph node-negative breast cancer it is important to identify high-risk patients who would benefit from further adjuvant therapy.
We analyzed 162 node-negative breast cancer cases to determine the prognostic relevance of FAK expression, and we investigated the relationship of FAK with major associated signaling pathways (HER2, Src, Akt and extracellular regulated kinases) by immunohistochemistry and western blot analysis.
Elevated FAK expression did not predict patient outcome, in contrast to tumor grading (P = 0.005), Akt activation (P = 0.0383) and estrogen receptor status (P = 0.0033). Significant positive correlations were observed between elevated FAK expression and HER2 overexpression (P = 0.001), as well as phospho-Src Tyr-215 (P = 0.021) and phospho-Akt (P < 0.001), but not with phospho-ERK1/2 (P = 0.108). Western blot analysis showed a significant correlation of FAK Tyr-861 activation and HER2 overexpression (P = 0.01).
Immunohistochemical detection of FAK expression is of no prognostic significance in node-negative breast cancer but provides evidence that HER2 is involved in tumor malignancy and metastatic ability of breast cancer through a novel signaling pathway participating FAK and Src.
粘着斑激酶(FAK)调节多种细胞过程,包括生长、分化、粘附、迁移和凋亡。在乳腺癌中,FAK过表达与癌症进展相关,但预后相关性仍不清楚。特别是对于淋巴结阴性乳腺癌,确定能从进一步辅助治疗中获益的高危患者很重要。
我们分析了162例淋巴结阴性乳腺癌病例,以确定FAK表达的预后相关性,并通过免疫组织化学和蛋白质印迹分析研究了FAK与主要相关信号通路(HER2、Src、Akt和细胞外调节激酶)之间的关系。
与肿瘤分级(P = 0.005)、Akt激活(P = 0.0383)和雌激素受体状态(P = 0.0033)相反,FAK表达升高并不能预测患者预后。FAK表达升高与HER2过表达(P = 0.001)、磷酸化Src Tyr-215(P = 0.021)和磷酸化Akt(P < 0.001)之间存在显著正相关,但与磷酸化ERK1/2无关(P = 0.108)。蛋白质印迹分析显示FAK Tyr-861激活与HER2过表达之间存在显著相关性(P = 0.01)。
在淋巴结阴性乳腺癌中,免疫组织化学检测FAK表达无预后意义,但提供了证据表明HER2通过参与FAK和Src的新信号通路参与乳腺癌的肿瘤恶性和转移能力。